Trump Executive Order Targets Drug Pricing Reform
Trump Executive Order Targets Drug Pricing Reform

Trump Executive Order Targets Drug Pricing Reform

News summary

President Donald Trump signed an executive order instituting a 'Most Favoured Nation' drug pricing policy, aiming to align U.S. prescription drug prices for branded and patented medications with those in the lowest-cost developed countries. The policy bypasses intermediaries like pharmacy benefit managers and is seen as favoring direct-to-government purchases, leaving the generics and biosimilars sectors largely unaffected. European and Irish officials have raised concerns about the order's impact on their pharmaceutical manufacturing and exports, while Indian companies view it as a market opportunity. Experts remain skeptical about the policy's legality and feasibility, referencing previous court challenges and anticipated industry resistance. The order has also entered ongoing negotiations between the Trump administration and drugmakers as a bargaining chip. Meanwhile, the U.S. has reported a notable decrease in fentanyl overdose deaths, though future access to treatments may be influenced by regulatory and funding changes.

Story Coverage
Bias Distribution
43% Left
Information Sources
bfb2a97b-336e-48d9-b69a-147df7862dc2590f0115-7f1b-422d-91c7-98a5c6a635300319a078-c5a7-4188-95f2-60cb4be32cc63de3a42a-679f-4933-9294-ef9df5494c53
+56
Left 43%
Center 22%
Right 35%
Coverage Details
Total News Sources
75
Left
26
Center
13
Right
21
Unrated
15
Last Updated
33 days ago
Bias Distribution
43% Left
Related News
Daily Index

Negative

32Serious

Neutral

Optimistic

Positive

Ask VT AI
Story Coverage
Subscribe

Stay in the know

Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Present

Gift Subscriptions

The perfect gift for understanding
news from all angles.

Related News
Recommended News